Systematic review of Shenqi Fuzheng Injection combined with chemotherapy for treatment of breast cancer.
10.19540/j.cnki.cjcmm.20180925.003
- Author:
Jia-Huan WU
1
;
Bao-Cheng XIE
1
;
Qing-Hui WANG
1
;
Chen-Hui ZHOU
2
;
Dao-Hua XU
3
Author Information
1. School of Pharmacy, Guangdong Medical University Dongguan 523808, China.
2. School of Nursing, Guangdong Medical University Dongguan 523808, China.
3. School of Pharmacy, Guangdong Medical University Dongguan 523808, China Institute of Traditional Chinese Medicine and New Pharmacy Development, Guangdong Medical University Dongguan 523808, China.
- Publication Type:Journal Article
- Keywords:
Meta-analysis;
Shenqi Fuzheng Injection;
breast cancer;
chemotherapy;
randomized controlled trials
- MeSH:
Antineoplastic Agents;
therapeutic use;
Breast Neoplasms;
drug therapy;
China;
Drugs, Chinese Herbal;
therapeutic use;
Female;
Humans;
Randomized Controlled Trials as Topic;
T-Lymphocyte Subsets
- From:
China Journal of Chinese Materia Medica
2019;44(3):589-596
- CountryChina
- Language:Chinese
-
Abstract:
Databases including China Biological Medicine database(CBM), Chinese scientific journals full-text database(VIP), China National Knowledge Infrastructure database(CNKI), WanFang Data, PubMed, and EMbase were searched from inception to March 2018 to collect the randomized controlled trials(RCTs) on Shenqi Fuzheng Injection combined with chemotherapy for the treatment of breast cancer. All included studies were critically appraised by two independent reviewers by following the cochrane systematic review method and using Revman 5.3 software and State 12.0 for data analysis. After screening, 20 RCTs involving 2 095 patients were included in the study. Meta-analysis showed that as compared with control group of chemotherapy alone, Shenqi Fuzheng Injection combined with chemotherapy could improve the clinical curative efficiency, the KPS score, and immune function indexes such as total T cells, Th cells and Ts cells; inhibit the decline of white blood cells(WBC), platelets in blood system, T-lymphocyte subsets such as CD3~+, CD4~+, CD4~+/CD8~+, alleviate myelosuppression and reduce the incidence of side effects such as gastrointestinal adverse reaction, liver and kidney dysfunction and abnormal electrocardiogram. The results revealed that for clinical breast cancer patients, Shenqi Fuzheng Injection combined with chemotherapy could significantly improve its clinical efficacy and reduce adverse reactions. However, the conclusions still need to be verified by high-quality, multi-center, large-sample, prospective, randomized and double-blind clinical trials. In conclusion, this study has systemically evaluated the efficacy and safety of Shenqi Fuzheng Injection combined with chemotherapy in treatment of breast cancer and provided the reference of evidence-based medicine for safe and effective clinical application of medicines.
